<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979301</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 16-008736</org_study_id>
    <nct_id>NCT02979301</nct_id>
  </id_info>
  <brief_title>Impact of Low-dose Tamoxifen on BPU</brief_title>
  <official_title>Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine whether changes in background parenchymal uptake (BPU) on molecular
      breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen. Women who have
      previously had high BPU on MBI will be recruited. Participants will take low-dose tamoxifen
      for a 30-day period, with post-tamoxifen MBI in order to investigate the impact of tamoxifen
      on BPU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)</measure>
    <time_frame>30 days</time_frame>
    <description>An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>High Background Uptake on MBI</condition>
  <arm_group>
    <arm_group_label>Tamoxifen 5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with high background uptake on MBI take 5 mg tam per day for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with high background uptake on MBI take 10 mg tam per day for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>5 mg or 10 mg tamoxifen per day for 30 days.</description>
    <arm_group_label>Tamoxifen 10 mg/day</arm_group_label>
    <arm_group_label>Tamoxifen 5 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:The following are requirements for entry into the study:

          1. Female, age 40 or older at the time of enrollment

          2. Most recent MBI examination, performed within 3 years of enrollment, showed moderate
             or marked background parenchymal uptake

          3. Mammogram performed within 12 months prior to enrollment that is available for
             comparison

          4. Willing and able to return for MBI following 30 days of low-dose tamoxifen

          5. If able to become pregnant

               1. Negative pregnancy test within 48 hours prior to study MBI exam(s)

               2. Agrees to avoid pregnancy during the study and for at least 2 months after study
                  participation ends, by abstinence, barrier method, or nonhormonal contraception.

          6. Understands and signs the consent form

             -

        Exclusion Criteria:Subjects will be excluded if any of the following characteristics are
        present:

        1) Evidence of suspected breast disease as defined by positive findings or recommendation
        for short-interval follow-up on most recent breast imaging (including mammography, MBI,
        MRI, ultrasound, etc.) not yet resolved prior to enrollment 2) Breast biopsy or breast
        surgery performed 6 months prior to enrollment 3) Bilateral breast implants or status
        post-bilateral prophylactic mastectomy 4) Pregnant or lactating 5) Current or recent use
        (within 6 months prior to enrollment) of any of the following drugs:

          1. Systemic hormonal therapy (oral or transdermal patch formulations)

          2. Hormonal contraception (oral, transdermal, implanted, or injected formulations)

          3. Selective estrogen receptor modulators (tamoxifen, raloxifene, or toremifene)

          4. Aromatase inhibitors (anastrazole, letrozole, or exemestane)

          5. GnRH analogs

          6. Prolactin inhibitors

          7. Androgens or antiandrogens

          8. Anticoagulants or &quot;blood thinners&quot; (warfarin, heparin, rivaroxaban and other novel
             anticoagulants)

          9. Drugs known to be strong inhibitors of CYP2D6, the major P450 enzyme that metabolizes
             tamoxifen, including:

               -  bupropion (Wellbutrin)

               -  fluoxetine (Prozac)

               -  paroxetine (Paxil)

               -  quinidine (Quinidex) 6) Personal history of any type of malignancy, with the
                  exclusion of non-melanoma skin cancer, diagnosed prior to enrollment 7) Personal
                  history or strong family history of blood clots in legs or lungs (also known as
                  deep vein thrombosis or pulmonary embolism) 8) Personal history of transient
                  ischemic attack (TIA) or cerebrovascular accident (CVA) 9) Active proliferative
                  disorders of the endometrium such as atypical hyperplasia, history of active
                  endometriosis, unresected polyps 10) Any type of retinal disorders or severe
                  cataract 11) Current or former smoker 12) Known carrier of BRCA1 or BRCA2 genetic
                  mutation or known DNA repair defect.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carrie Hruska, PhD R-D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <results_first_submitted>April 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Carrie Hruska</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02979301/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tamoxifen 5 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 5 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
        <group group_id="P2">
          <title>Tamoxifen 10 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 10 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tamoxifen 5 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 5 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
        <group group_id="B2">
          <title>Tamoxifen 10 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 10 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="4.4"/>
                    <measurement group_id="B2" value="48.1" spread="4.0"/>
                    <measurement group_id="B3" value="47.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)</title>
        <description>An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen 5 mg/Day</title>
            <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 5 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen 10 mg/Day</title>
            <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 10 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI)</title>
          <description>An image analysis tool to obtain a quantitative measure of background parenchymal uptake (BPU) was applied to pre-tamoxifen and post-tamoxifen MBI exams. The percent change in BPU from pre-tamoxifen to post-tamoxifen MBI was determined.</description>
          <units>percent change in BPU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="21"/>
                    <measurement group_id="O2" value="-12" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline until the last study visit for each study subject, approximately 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tamoxifen 5 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 5 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
        <group group_id="E2">
          <title>Tamoxifen 10 mg/Day</title>
          <description>Women with a history of high background uptake on MBI were enrolled.
A baseline MBI was performed at Day 0. Women then took 10 mg tamoxifen per day for 30 days, followed by a post-tamoxifen MBI exam.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carrie Hruska</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-293-4719</phone>
      <email>hruska.carrie@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

